Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency may leads to lower local adverse events: skin thinning; end of treatment (2‐5 weeks) compared with mild‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
It is very uncertain whether moderate‐potency changes systemic adverse events: abnormal cortisol; end of treatment (6‐28… compared with mild‐potency topical corticosteroid (very low certainty).
1 finding from 1 review
Adverse events (moderate) · adolescent and adult male circumcisions
Circumcision devices showed no clear difference in moderate adverse events compared with standard surgical techniques (low certainty).
1 finding from 1 review
Adverse events (moderate) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (moderate) compared with stereotactic radiosurgery (very low certainty).
1 finding from 1 review
Adverse events (moderate) · people with single or solitary brain metastasis
It is very uncertain whether surgery plus whole brain radiotherapy (WBRT) changes adverse events (moderate) compared with stereotactic radiosurgery plus WBRT (very low certainty).
1 finding from 1 review
Adverse events Mild to moderate swelling · Patients with thumb (trapeziometacarpal joint) osteoarthritis
It is very uncertain whether trapeziectomy with interpositional arthroplasty (T and IA) changes adverse events Mild to moderate swelling compared with artelon joint resurfacing (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: number of moderate adverse events · adults and children with cystic fibrosis and P aeruginosa
The intervention showed no clear difference in adverse events: number of moderate adverse events (moderate certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (16 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (16 weeks) · IBD patients
It is very uncertain whether IV iron sucrose changes serious adverse events ‐ mild to moderate disease (20 weeks) compared with oral iron sulphate (very low certainty).
1 finding from 1 review
Serious adverse events ‐ mild to moderate disease (12 weeks) · IBD patients
It is very uncertain whether IV ferric carboxymaltose changes serious adverse events ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (very low certainty).
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · children and young adults with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
Intervention not reported
Adverse events: a. mild to moderate hypoglycaemia (episodes per participant)
1 finding from 1 review
Adverse events (moderate) · adults and children with cystic fibrosis (during acute exacerbations of lung disease)
It is very uncertain whether summary of findings: Inhaled antibiotics plus IV antibiotics changes adverse events moderate adverse events experienced during and after… compared with IV antibiotics only (very low certainty).
1 finding from 1 review
Primary outcome: adverse events (assessed at 3 months as minimum, moderate or severe) · ulceration caused by nerve damage in leprosy
1 finding from 1 review
Adverse events: gastrointestinal – dyspeptic symptoms – self‐assessed as at least 'moderate' · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes adverse events: gastrointestinal – dyspeptic symptoms –… compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).
1 finding from 1 review
Adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in adverse events compared with conventional dosing (moderate certainty).
1 finding from 1 review